Literature DB >> 8254833

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.

H A Feldman1, I Goldstein, D G Hatzichristou, R J Krane, J B McKinlay.   

Abstract

We provide current, normative data on the prevalence of impotence, and its physiological and psychosocial correlates in a general population using results from the Massachusetts Male Aging Study. The Massachusetts Male Aging Study was a community based, random sample observational survey of noninstitutionalized men 40 to 70 years old conducted from 1987 to 1989 in cities and towns near Boston, Massachusetts. Blood samples, physiological measures, socio-demographic variables, psychological indexes, and information on health status, medications, smoking and lifestyle were collected by trained interviewers in the subject's home. A self-administered sexual activity questionnaire was used to characterize erectile potency. The combined prevalence of minimal, moderate and complete impotence was 52%. The prevalence of complete impotence tripled from 5 to 15% between subject ages 40 and 70 years. Subject age was the variable most strongly associated with impotence. After adjustment for age, a higher probability of impotence was directly correlated with heart disease, hypertension, diabetes, associated medications, and indexes of anger and depression, and inversely correlated with serum dehydroepiandrosterone, high density lipoprotein cholesterol and an index of dominant personality. Cigarette smoking was associated with a greater probability of complete impotence in men with heart disease and hypertension. We conclude that impotence is a major health concern in light of the high prevalence, is strongly associated with age, has multiple determinants, including some risk factors for vascular disease, and may be due partly to modifiable para-aging phenomena.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8254833     DOI: 10.1016/s0022-5347(17)34871-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  699 in total

Review 1.  Sexual side effects of antidepressant drugs.

Authors:  A J Gelenberg; P Delgado; H G Nurnberg
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

Review 2.  Recent advances in female sexual dysfunction.

Authors:  A R Davis
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

3.  Sildenafil and erectile dysfunction.

Authors:  A Fabbri; A Aversa; A Isidori
Journal:  J Endocrinol Invest       Date:  1999-06       Impact factor: 4.256

4.  Viagra and broken hearts.

Authors:  S Holzapfel
Journal:  Can Fam Physician       Date:  2000-02       Impact factor: 3.275

5.  Health-related quality of life in a UK-based population of men with erectile dysfunction.

Authors:  Julian F Guest; Roben Das Gupta
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  Sexual behaviour and its medicalisation: in sickness and in health.

Authors:  Graham Hart; Kaye Wellings
Journal:  BMJ       Date:  2002-04-13

7.  Measurement of male and female sexual dysfunction.

Authors:  R C Rosen
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

8.  Erectile dysfunction in opioid users: lack of association with serum testosterone.

Authors:  Patricia A Cioe; Peter D Friedmann; Michael D Stein
Journal:  J Addict Dis       Date:  2010-10

9.  The effect of sildenafil citrate and pentoxifylline combined treatment in the management of erectile dysfunction.

Authors:  Ozdem Levent Ozdal; Cuneyt Ozden; Serkan Gokkaya; Guvenc Urgancioglu; Binhan Kagan Aktas; Ali Memis
Journal:  Int Urol Nephrol       Date:  2007-09-01       Impact factor: 2.370

10.  TNF-alpha knockout mice have increased corpora cavernosa relaxation.

Authors:  Fernando S Carneiro; Lashon C Sturgis; Fernanda R C Giachini; Zidonia N Carneiro; Victor V Lima; Brandi M Wynne; Sebastian San Martin; Michael W Brands; Rita C Tostes; R Clinton Webb
Journal:  J Sex Med       Date:  2009-01       Impact factor: 3.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.